Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27729376 | 0.98 | HRH3 (0.51) | HRH3NCF1ALDH1A1MEN1KMT2A | |
| SCHEMBL27780446 | 0.94 | NCF1 (0.48) | HRH3NCF1ALDH1A1MEN1KMT2A | |
| SCHEMBL27829415 | 0.89 | HRH3 (0.54) | HRH3NCF1ALDH1A1HTTKDM4E | |
| SCHEMBL27809061 | 0.87 | NCF1 (0.58) | HRH3NCF1ALDH1A1HTTKDM4E | |
| SCHEMBL23113743 | 0.84 | HRH3 (0.47) | HRH3NCF1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL845155 | 0.84 | HRH3 (0.52) | HRH3NCF1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3149449 | 0.84 | NCF1 (0.55) | HRH3NCF1ALDH1A1HTTKDM4E | |
| SCHEMBL5395459 | 0.83 | SIGMAR1 (0.53) | ALDH1A1MEN1KMT2APOLBSIGMAR1 | |
| SCHEMBL3145370 | 0.83 | HRH3 (0.68) | HRH3NCF1ALDH1A1MEN1KMT2A | |
| SCHEMBL161004 | 0.82 | HRH3 (0.55) | HRH3NCF1ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GFB (ABC), LLC | 2022-12-08 | — | — | US | claimed |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | MEI PHARMA, INC. | 2022-10-13 | — | — | US | claimed |
| CN-114787160-A | Imidazopyridazines and imidazopyridines as activin receptor-like kinase-2 inhibitors | 因赛特公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114761000-A | Substituted 1, 6-naphthyridine inhibitors of CDK5 | 金翅雀生物公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | claimed |
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| CN-113149885-A | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-07-23 | — | — | CN | claimed |
| WO-2021067569-A1 | SUBSTITUTED 1, 6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2021-04-08 | — | — | WO | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10335415-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | MEI PHARMA, INC. (US) | 2019-07-02 | — | — | US | claimed |
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-01-05 | — | — | US | claimed |
| CN-1556807-A | Chemical compounds | �㶫��������ҽҩ�ɷ�����˾ | 2004-12-22 | — | — | CN | claimed |
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | claimed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | claimed |
| US-6627624-B1 | Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, | NEUROGEN CORPORATION | 2003-09-30 | — | — | US | claimed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | claimed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | claimed |
| US-5733867-A | CHOLECYSTOKININS AND GASTRIN ANTAGONIST | GLAXO WELLCOME SPA (IT) | 1998-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004002-A1 | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors | SRC, LCK, FYN | HRH3 495/4885NCF1 787/4885ALDH1A1 4583/4885 |
| US-20220323449-A1 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES | CCNI, CCNK, CCNA1 | HRH3 1686/4885NCF1 2240/4885ALDH1A1 208/4885 |
| US-10335415-B2 | (Alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | CCNI, CCNK, CCNA1 | HRH3 1686/4885NCF1 2240/4885ALDH1A1 208/4885 |
| US-20220389009-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | CDK5, CDK5R1, PKD1 | HRH3 4071/4885NCF1 214/4885ALDH1A1 2375/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | HRH3 3252/4885NCF1 1958/4885ALDH1A1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.